Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer

Journal of Clinical Oncology

Volumn 23, Issue 13, 2005, Pages 2996-3000

  Andre, Fabrice ^a   Khalil, Ahmed ^a   Slimane, Khemaies ^a   Massard, Christophe ^a   Mathieu, Marie Christine ^a   Vignot, Stéphane ^a   Assi, Hazem ^a   Delaloge, Suzette ^a   Spielmann, Marc ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MITOSIS; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETICS; MIDDLE AGED; MITOSIS INDEX; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; MITOTIC INDEX; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 19444385413     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.046     Document Type: Article

References (21)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
2. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365, 2003
3. Hamilton A, Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11:647-663, 2000
4. Stal O, Dufmats M, Hatschek T, et al: S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 11:1717-1722, 1993
5. Daidone MG, Silvestrini R: Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr 30:27-35, 2001
6. Arriagada R, Spielmann M, Koscielny S, et al: Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen. Ann Oncol 13:1378-1386, 2002
7. Tursz T, Arriagada R, Koscielny S, et al: Patterns of failure in two randomized trials of adjuvant anthracycline-based chemotherapy in 1,146 patients with early breast cancer. Proc Am Soc Clin Oncol 22:10, 2003 (abstr A36)
8. Contesso G, Mouriesse H, Friedman S, et al: The importance of histologic grade in long-term prognosis of breast cancer: A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 5:1378-1386, 1987
9. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 30:5-15, 2001
10. Aas T, Geisler S, Eide GE, et al: Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 39:438-446, 2003
11. MacGrogan G, Mauriac L, Durand M, et al: Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74:1458-1465, 1996
12. Amadori D, Nanni O, Marangolo M, et al: Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: A randomized multicenter study. J Clin Oncol 18:3125-3134, 2000
13. Stal O, Skoog L, Rutqvist LE, et al: S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 70:1258-1262, 1994
14. Pronzato P, Queirolo P, Vecchio S, et al: Thymidine labeling index analysis in early breast cancer patients randomized to receive perioperative chemotherapy. Oncology 60:88-93, 2001
15. Simpson JF, Gray R, Dressler LG, et al: Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18:2059-2069, 2000
16. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602-611, 2001
17. Di Leo A, Larsimont D, Gancberg D, et al: HER-2 and topoisomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12:1081-1089, 2001
18. Zemzoum I, Kates RE, Ross JS, et al: Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 21:1022-1028, 2003
19. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002
20. Depowski PL, Rosenthal SI, Brien TP, et al: Topoisomerase II alpha expression in breast cancer: Correlation with outcome variables. Mod Pathol 13:542-547, 2000
21. Van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002